SLC5A2 and type 2 diabetes mellitus: Considering the benefit that SGLT-2 inhibitors provide to patients with type 2 diabetes mellitus (T2DM) and known cardiovascular disease, it draws attention to the low prescription rate of these therapies among cardiologists [14] and the lack of scientific evidence for their use at hospital discharge.